Publix Q1 net earnings down 21.5% to $794M; stock price raised to $20.45

PUBLIX SUPER MARKETS INC

Sales $16.1B, up 2% YoY; comparable store sales unchanged.
Net earnings $794M (-21.5% YoY); EPS $0.25 vs $0.31 (2025).
Excluding unrealized losses, adjusted EPS $0.36 in both quarters.
Sales growth slowed by Medicare MFP change on 10 drugs effective Jan 2026.
Stock price increased from $19.65 to $20.45 per share effective May 1, 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PUBLIX SUPER MARKETS INC reported the three months ended March 28, 2026 results: revenue $16.1 billion, net income $794 million, EPS $0.25 per share.

Period: the three months ended March 28, 2026
Revenue: $16.1 billion
Net income: $794 million
EPS: $0.25 per share
Result: reported results

Exact text from the filing

Publix’s sales for the three months ended March 28, 2026 were $16.1 billion, a 2% increase from $15.8 billion in 2025. The increase in sales for the three months ended March 28, 2026 compared to the three months ended March 29, 2025 was lower due to the impact of the Medicare maximum fair price (MFP) change effective January 1, 2026 which reduced drug prices for 10 drugs. The impact of the MFP change resulted in a decrease in sales. Comparable store sales for the three months ended March 28, 2026 remained unchanged. Net earnings for the three months ended March 28, 2026 were $794 million, compared to $1 billion in 2025, a decrease of 21.5%. Earnings per share for the three months ended March 28, 2026 decreased to $0.25 per share, down from $0.31 per share in 2025.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000081061-26-000059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.